On June 11, 2026, the 2nd Global Ophthalmology Conference was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

As an important component of MedTech (Siyu MedTech)'s annual MedTech conference series, this year's conference attracted over 600 professional guests from hospitals, research institutes, innovative enterprises, investment institutions, and industrial service platforms. The Ophthalmology Conference focused on directions such as ophthalmic innovative devices, intraocular lenses, ophthalmic imaging, myopia prevention and control, ophthalmic digitalization, neuro-ophthalmology, and clinical application innovation, gathering representatives from both industry and clinical practice to jointly explore the latest progress and implementation pathways of ophthalmic medical technology innovation.

On-site at the conference, the 2026 Global Ophthalmology Innovation Awards were unveiled. This year's awards included two categories: the Ophthalmology Innovative Device Award and the Ophthalmology Application Innovation Award. The Ophthalmology Innovative Device Award primarily focused on representative enterprises that had obtained innovative product registration approval from the National Medical Products Administration (NMPA), entered the Special Review Program for Innovative Medical Devices, or achieved breakthroughs in key ophthalmic technologies. The Ophthalmology Application Innovation Award focused on the application value of ophthalmic products, technologies, and services in clinical diagnosis and treatment, screening and prevention, digital management, and medical service systems.

Note: MedTech organizes awards twice annually. The judging panel can only select from registered applicants. Therefore, please follow the announcements and actively apply to participate.

The award winners are listed below (in no particular order).

2026 Global MedTech — Ophthalmology Innovative Device Award

(2 Winners)

Nanochap

Award Citation:

Hangzhou Nanochap Electronics Technology Co., Ltd. was founded in 2014 and has long focused on frontier technology R&D such as brain-computer interfaces and biochips, forming a relatively complete technical capability across links including chip design, packaging, implantable components, and medical terminals.

The company's visual brain-computer interface product addresses the visual reconstruction needs of patients with total blindness or visual field loss. It has completed multiple animal experiments, passed medical device type testing, and recently completed China's first visual brain-computer interface GCP clinical trial. Moreover, the patient was able to clearly recognize letters on the second day after device activation. This is currently the fastest publicly reported record for restored visual perception, fully demonstrating China's domestic innovation strength and leading progress in the field of visual reconstruction.

The visual brain-computer interface is an important direction at the intersection of ophthalmology, brain science, chip engineering, and neuromodulation. Nanochap has continuously tackled key issues such as high-resolution electrical stimulation, implant miniaturization, hermetic sealing, dynamic parameter regulation, and charge balance, providing a representative case for domestic invasive visual brain-computer interface products moving from R&D verification toward clinical transformation.

CENTURY HEALTHCARE

Award Citation:

Tianjin Century Healthcare Biomedical Engineering Co., Ltd. is an ophthalmic medical device enterprise integrating R&D, production, and sales, long focusing on intraocular lens and optometry product R&D, and has formed a product system covering hydrophilic, hydrophobic, monofocal, and multifocal directions.

The company's Liangshi'an® Trifocal Plus Intraocular Lens received NMPA approval in 2025 and is classified as an innovative medical device. This product addresses the full-range vision needs after cataract surgery, adopting patented design related to targeted light field distribution, optimizing continuity across far, intermediate, and near vision distances and light energy utilization efficiency. This product is also the only ophthalmic product among NMED (National High-Performance Medical Device Innovation Center)'s "2025 Innovative Medical Device Product Rising Stars." The company's another innovative medical device, Wanshi'an® Ultra-EDoF Extended Depth of Focus Intraocular Lens, also received NMPA approval in 2025, further enriching the domestic high-end functional intraocular lens product options.

As one of the few domestic enterprises with multiple approved innovative intraocular lens products, CENTURY HEALTHCARE has formed a relatively systematic technical layout in the domestic high-end intraocular lens field, providing more domestic options for improved postoperative visual quality in cataract patients.

2026 Global MedTech — Ophthalmology Application Innovation Award

(10 Winners)

BigVision

Award Citation:

Suzhou BigVision Medical Technology Co., Ltd. focuses on R&D of ophthalmic imaging AI analysis and diagnosis software and hardware systems, forming a product portfolio around multimodal AI analysis and diagnosis software for fundus imaging, as well as intelligent hardware such as OCT, ultra-wide-angle fundus cameras, and dry eye detection devices, empowering ophthalmic diagnosis and treatment with hardcore technology and striving to build a globally leading ophthalmic AI brand.

The company's ophthalmic OCT image-assisted diagnosis software MIAS-3000 received a Class III medical device registration certificate in 2025. This software addresses OCT image-assisted diagnosis scenarios for fundus diseases, has been validated through multicenter clinical trials, and can assist physicians in disease identification and staging judgment. It was also selected as a winning unit in the MIIT Artificial Intelligence Medical Device Innovation Task "Open Competition".

The clinical value of ophthalmic AI lies in whether it can truly embed into clinical workflows, help improve screening efficiency, reduce missed diagnosis and misdiagnosis risks, and serve grassroots medical institutions. The approval and implementation of BigVision MIAS-3000 provides a representative case for ophthalmic imaging AI moving from algorithm research to compliant clinical application.

INTALIGHT

Award Citation:

INTALIGHT has long focused on R&D and manufacturing of high-end ophthalmic diagnosis and treatment equipment, forming the "Ruyi" series ophthalmic diagnostic product matrix around directions such as ultra-wide-angle imaging, swept-source technology, femtosecond lasers, and artificial intelligence.

In 2026, the company globally launched the "Ruyi 600" 600kHz commercial swept-source OCT and the dual ultra-wide-angle modular multimodal imaging platform "Ruyi Center." Among them, the Ruyi 600 can complete 150° ultra-wide-angle OCTA scanning in 5 seconds, achieving ultra-high-speed precision imaging. The Ruyi Center serves as the connection hub for the Ruyi series products, enabling cross-product multimodal combination and digital connectivity, from rapid acquisition to multimodal collaboration, opening a new workflow for fundus imaging.

The company's core product, Ruyi Full-Eye OCT, focuses on full-eye imaging and ultra-wide-angle OCTA applications, further expanding the boundaries of ophthalmic imaging diagnosis, and has now achieved over 1,000 global installations. The Ruyi True-Color Camera adopts multi-light-source continuous spectrum true-color imaging technology, with a single imaging range of 186°, comprehensively improving the efficiency of fundus disease diagnosis, teaching, and physician-patient communication. The Ruyi Full-Corneal Biometer adopts new swept-source technology, combining panoramic visualized fundus imaging mode with a self-developed telecentric optical system, with built-in advanced IOL calculation formulas, serving cataract preoperative assessment and intraocular lens power calculation.

INTALIGHT's award value lies in having built an ophthalmic diagnostic equipment system covering fundus, cornea, biometry, and OCT through continuous innovation in optical systems, imaging platforms, and AI algorithms, and driving ophthalmic imaging toward ultra-wide-angle, ultra-high-speed, and intelligent directions through innovative achievements such as "Ruyi Center" and "Ruyi 600," providing more complete and more efficient imaging and measurement tools for ophthalmic clinical practice.

Shijing Medical

Award Citation:

Guangzhou Shijing Medical Software Co., Ltd. was founded in 2008 and is a leading domestic visual health comprehensive solution provider, with well-known brands such as "Beibeile" and "Duobaoshi" under its umbrella, covering fields such as visual training, PBM photobiomodulation, and myopia prevention and control. The company is committed to driving the optometry industry from traditional lens fitting toward professional eye health management through technological innovation and ecosystem co-construction.

The company's subsidiary Guanglang Biotechnology's Beibeile PBM-LED Red Light Myopia Treatment Device received a Class II medical device registration certificate in 2025, becoming the first approved medical device after the national red light policy. This product features quadruple protection and 10x safety redundancy, far exceeding international authoritative safety standards; adopts a ten-step parameter chain optical path design for efficient axial length and diopter control; and clinical studies have confirmed that Beibeile can effectively delay axial length growth. Originating from photobiomodulation technology and addressing adolescent myopia prevention and control scenarios, Beibeile provides a new intervention tool for axial length growth control and myopia management.

Myopia prevention and control is a long-term priority in ophthalmic public health and clinical services. Shijing Medical has formed a continuous layout around digital therapeutics, photobiological therapy, and optometry management platforms, driving myopia prevention and control from single examination and lens fitting services toward the integrated direction of screening, intervention, follow-up, and digital management.

ASK

Award Citation:

ASK Medical Technology was founded in 2021, focusing on R&D, production, and services of software and hardware products in the ophthalmic and optometry fields, covering multiple eye health management scenarios such as homes, schools, communities, and medical institutions. Currently, the company has formed three core product systems: ophthalmic precision diagnosis and treatment solutions, optometry store solutions, and campus screening solutions.

The company's ophthalmic optical biometer "Swan" addresses axial length measurement needs in scenarios such as myopia management, innovating in multispectral low-reflection technology and peripheral axial length measurement. The product improves examination efficiency and data consistency through multi-parameter parallel acquisition and low-reflection signal optimization; its peripheral fixation system can guide off-axis gaze, achieving axial length measurement at multiple angles in the nasal-temporal and superior-inferior directions.

As myopia prevention and control enters the refined management stage, single central axial length data is no longer sufficient to meet personalized assessment needs. ASK provides new data dimensions for myopia occurrence and development monitoring and personalized intervention assessment through the expansion of parameters such as peripheral axial length.

HAOHAI HEALTH

Award Citation:

As China's first "H+STAR Market" biomedical pharmaceutical listed company, Shanghai HAOHAI HEALTH Technology Co., Ltd. has long laid out treatment fields such as ophthalmology, aesthetic medicine, orthopedics, and surgery. HAOHAI Ophthalmology has been deeply engaged in ophthalmology for 18 years, based locally with a global vision, and its business has covered multiple segments such as cataracts, optometry, refractive surgery, ocular surface, and fundus diseases, forming a terminal product pipeline covering the full life cycle of eye health.

The company's Quanshijia® is the world's first five-focus diffractive intraocular lens with Fourier harmonic five-focus diffractive intraocular lens patented technology design, based on the company's self-developed COMPLUSAGE® (Complete Light Usage) technology. Through innovative five-focus Fourier harmonic diffractive design, it achieves nearly 100% light energy utilization under pupil diameters smaller than 3.5mm, building more continuous and smooth visual transitions between far, intermediate, and near vision, effectively improving intermediate vision compared to trifocal lenses. Notably, the company's another innovative product, Xiangwujie® Phase-Optimized Trifocal Intraocular Lens, has received NMPA approval through the Special Approval Channel for Innovative Medical Devices due to its technological innovation and clinical value, with its astigmatism-correcting version expected to receive approval within this year.

HAOHAI HEALTH's award value lies in breaking the technical bottleneck of traditional multifocal intraocular lenses designed using Fresnel principles with self-developed innovative technology, not only providing domestic solutions for cataract patients that combine excellent visual quality with clinical accessibility, but also further validating the feasible pathway of original technological breakthroughs under the medical-engineering collaborative model. Simultaneously, it provides strong empirical evidence for the domestic high-end ophthalmic consumables leap from "following" to "leading," driving the industry toward a new pattern defined by technology.

GAUSH

Award Citation:

Gaush Innovation Technology Co., Ltd. is the ophthalmic active medical device R&D and production platform under Gaush Medical Technology Group, located in the Wuxi Xishan District Precision Medical Industrial Park. Relying on the group's long-term accumulation in the ophthalmic field, it continuously promotes R&D and domestic production of high-end ophthalmic diagnostic equipment.

The company's self-developed corneal confocal microscope T3 series addresses corneal in-vivo cellular-level imaging needs, achieving technical balance between wide field of view and high resolution. This product achieves high-resolution imaging under a large scanning field of view through laser light source and confocal tomography scanning technology, and can be used to observe in-vivo corneal cellular structures at various layers.

In clinical application, the corneal confocal microscope can provide imaging evidence for the diagnosis, follow-up, and pathological research of infectious keratitis, keratoconus, dry eye, and other corneal and conjunctival diseases. The launch of Gaush Innovation T3 series reflects the continuous breakthrough of domestic ophthalmic diagnostic equipment in specialized clinical scenarios.

FEMTOMARCH

Award Citation:

Shenzhen FEMTOMARCH Medical Technology Co., Ltd. was founded in 2022, focusing on clinical transformation of femtosecond lasers in ophthalmic surgery, primarily developing ophthalmic femtosecond laser treatment systems.

The company focuses on domestic production needs for high-end refractive and corneal surgical equipment, concentrating on personalized all-femtosecond high-order aberration correction, and carries out independent R&D of femtosecond laser core components and complete machine systems, with key focus on high-precision large-field three-dimensional optical scanning systems, medical-grade femtosecond lasers, real-time closed-loop monitoring and control technology, and customized refractive correction algorithms. In 2025, FEMTOMARCH's ophthalmic femtosecond laser treatment system production prototype passed national type testing and obtained the report.

Femtosecond laser treatment systems are an important direction in ophthalmic high-end surgical equipment, with long-standing high requirements for optics, lasers, control algorithms, and system integration capabilities. FEMTOMARCH's R&D progress provides a new industrial sample for domestic ophthalmic femtosecond laser equipment entering the clinical transformation and registration advancement stages.

EENT

Award Citation:

The relevant team at Fudan University Affiliated Eye, Ear, Nose and Throat Hospital has long focused on keratoconus and other ectatic corneal disease diagnosis and treatment, carrying out clinical research, mechanism exploration, and transformation application around corneal cross-linking technology.

Starting from clinical problems, the team has continuously promoted research in directions such as transepithelial corneal cross-linking, accelerated corneal cross-linking, corneal stromal oxygenation, and regional targeted corneal reinforcement, exploring more precise corneal reinforcement treatment plans. Related research results have been published in multiple international SCI academic journals, and have formed multiple patents and transformation achievements.

Keratoconus patients often face risks of vision decline, refractive error progression, and corneal transplantation. The team's systematic research around corneal cross-linking efficacy improvement and personalized treatment pathways provides important clinical and research support for optimization of corneal disease treatment methods, and also demonstrates the leading role of ophthalmic clinical teams in medical-engineering interdisciplinary transformation.

HUAXIA EYE

Award Citation:

Huaxia Eye Hospital Group Co., Ltd. has developed and applied the "Myopia Prevention and Control Campus Screening System 3.0" around children and adolescent myopia prevention and control scenarios, driving campus screening to upgrade from manual recording and decentralized management toward digitalization, standardization, and collaboration.

The system supports QR code identification, hardware direct connection, and real-time data upload, which can improve campus screening efficiency, and through intelligent myopia grading judgment, multi-dimensional visualized reports, and abnormal data identification, assists medical staff in completing screening management. The system simultaneously connects home-school service links, allowing parents to view vision reports and trends, and obtain report interpretation, online consultation, follow-up, and referral services through the Huaxia Smart Hospital mini-program.

Since its launch in 2026, the system has been applied in multiple hospitals and schools, completing large-scale screening. Its value lies in combining ophthalmic specialist capabilities, digital systems, and campus public health scenarios, providing a replicable service model for children and adolescent myopia prevention and control.

TFDAH of GDMU

Award Citation:

The Ophthalmology Center of the First Affiliated Hospital of Guangdong Medical University (Dongguan) (TFDAH of GDMU), under the leadership of Director Zhou Dan, has continuously promoted the implementation of new ophthalmic technologies in regional clinical scenarios in recent years, covering directions such as complex cataracts, minimally invasive glaucoma treatment, and vitreoretinal surgery.

The team has improved regional difficult eye disease diagnosis and treatment capabilities by carrying out technologies such as micropulse laser, refractive cataract surgery, and complex vitreoretinal surgery. Meanwhile, the hospital has established the "Glaucoma Home," forming a service closed loop around patient full-cycle diagnosis and treatment, follow-up management, and health education, and actively participating in public welfare and public health work such as Tibet aid vision missions, myopia prevention and control, and newborn fundus screening.

Its award value lies in combining new ophthalmic technologies, chronic disease management, and regional medical service capacity building, driving more ophthalmic diagnosis and treatment projects to land in grassroots and regional centers, and providing more continuous and more accessible ophthalmic medical services for patients.

Conclusion

From functional intraocular lenses and visual brain-computer interfaces, to corneal confocal microscopes, ophthalmic OCT AI, and myopia prevention and control digital systems, and further to femtosecond lasers, red light myopia intervention, and regional ophthalmic service innovation, this year's award-winning enterprises and institutions cover multiple key directions in ophthalmic technology innovation.

Among them, the Ophthalmology Innovative Device Award showcases the new progress of domestic ophthalmic products in NMPA innovative medical device approvals, innovative channel advancement, and frontier technology transformation. The Ophthalmology Application Innovation Award presents the landing value of ophthalmic technology in real clinical practice, public health, screening management, and digital services.

The significance of ophthalmic medical technology innovation ultimately manifests in more precise diagnosis, safer treatment, more continuous management, and broader accessibility. In the future, MedTech (Siyu MedTech) and EyeFuture will continue to focus on outstanding enterprises, institutions, and teams in the ophthalmic field with clinical value, technical content, and industrialization potential, jointly witnessing the continuous growth of China's ophthalmic innovation force.

June 11, 2026